Additional file 2 of Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis

Additional file 2: Table S1. Median expression of markers. Table S2. Mean and standard deviation of the percentage of each immune cell subset. Table S3. Mean and standard deviation of the percentage of each B cell subset among all CD19+ cells. Table S4. Median expression markers of migratory markers. Table S5. Median expression markers of migratory markers. Table S6. Mean and standard deviation of the percentage of each B cell subset among all CD45+ cells with follow-up sample. Table S7. Statistics of Δ. Table S8. Mean and standard deviation of the percentage of each B cell subset among all CD45+ cells with follow-up sample in GC patients.